Merz Declines to Raise Bid for Obagi, Yielding to Valeant

Merz Pharma GmbH walked away from an effort to buy Obagi Medical Products Inc., saying it didn’t want to top Valeant Pharmaceuticals International Inc.’s $418 million offer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.